Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.83
-0.15 (-1.88%)
At close: Jul 24, 2026, 4:00 PM EDT
7.80
-0.03 (-0.38%)
After-hours: Jul 24, 2026, 7:34 PM EDT

Solid Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----8.0913.62
Revenue Growth
-----40.57%-
Gross Profit
----8.0913.62
Operating Income
-196.46-179.21-129.73-104.25-106.45-72.25
Net Income
-191.78-174.33-124.7-96.02-85.98-72.19
Earnings Per Share
-1.95-1.99-3.06-4.83-10.10-10.14
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
381.32189.07148.92123.64213.72207.78
Total Debt
20.6721.1624.1826.2728.552.06
Net Cash (Debt)
360.65167.91124.7497.38185.18205.72
Net Cash Growth
27.31%34.61%28.11%-47.41%-9.98%37.52%
Net Cash Per Share
3.671.923.064.9021.7528.90

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-171.67-156.29-100.01-94.18-97.98-77.76
Capital Expenditures
-1.19-1.15-0.65-1.52-3.02-1.28
Free Cash Flow
-172.86-157.44-100.67-95.7-100.99-79.05
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----100.00%100.00%
Operating Margin
-----1315.20%-530.50%
Pretax Margin
-----1062.28%-530.01%
Profit Margin
-----1062.28%-530.01%
FCF Margin
-----1247.74%-580.36%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----13.0014.18